WO2005095623A1 - Procédé d'introduction d'un gène dans une cellule cible - Google Patents

Procédé d'introduction d'un gène dans une cellule cible Download PDF

Info

Publication number
WO2005095623A1
WO2005095623A1 PCT/JP2005/006182 JP2005006182W WO2005095623A1 WO 2005095623 A1 WO2005095623 A1 WO 2005095623A1 JP 2005006182 W JP2005006182 W JP 2005006182W WO 2005095623 A1 WO2005095623 A1 WO 2005095623A1
Authority
WO
WIPO (PCT)
Prior art keywords
vector
cell
gene
protein
target cell
Prior art date
Application number
PCT/JP2005/006182
Other languages
English (en)
Japanese (ja)
Inventor
Shuji Hayashi
Makoto Inoue
Mamoru Hasegawa
Original Assignee
Dnavec Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc. filed Critical Dnavec Research Inc.
Publication of WO2005095623A1 publication Critical patent/WO2005095623A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Definitions

  • the present invention relates to a method for introducing a gene under adverse conditions such as low-temperature, low-oxygen or short-term infection.
  • Gene transfer is a basic technique for genetic manipulation of cells and animals. Technology for gene transfer has been developed and improved in order to examine the function of a certain gene or gene product, or to use a gene whose gene function has been identified or to prevent or treat a disease. For humans, treatment of diseases by gene transfer is being studied as gene therapy.
  • Gene transfer methods include a physicochemical method such as a calcium phosphate method, an electoral poration method, and a method using a gene gun, and a biological method such as a transfer method using a virus vector.
  • Gene transfer by a biological method is generally performed by contacting a cell with a gene at room temperature under oxygen for a relatively long time. But in the clinic, low temperature, low oxygen, short contact! / ⁇ ⁇
  • gene transfer under special circumstances is required. For example, in genetic manipulation of the transplanted organ vasculature, the transplanted organ is removed from an organ donor, and a gene such as an immunosuppressive gene is introduced during storage of the organ under low temperature and low oxygen for a short time so as not to cause organ damage. There is a need. By transplanting this organ into patients, organ transplantation is possible without using immunosuppressants.
  • the adenovirus vector is capable of very efficiently introducing genes into both dividing and non-dividing cells, and is also capable of preparing a virus solution having a very high concentration. For example, it satisfies the conditions for in vivo gene transfer into living organisms.
  • the adenowill vector is one of the existing gene transfer vectors that is excellent in gene transfer efficiency into the vascular system (Lemarchand P et al., Proc Natl Acad Sci US A. 89 (14) , 6482—6486 (1992)). This is a typical example of the above-mentioned adverse conditions of low temperature, low oxygen, and short-term infection. Examination of the efficiency of gene transfer into transplanted organs revealed that the gene transfer efficiency and the expression level at low temperatures were significantly lower than at room temperature. Therefore, there is a need for a method for efficiently introducing a gene under such adverse conditions.
  • Non-patent literature l Lemarchand P et al., Proc Natl Acad Sci U S A. 89 (14), 6482-6486 (1992)
  • Non-Patent Document 2 Watkins SJ et al., Gene Ther. 4, 1004-1012 (1997)
  • Non-Patent Document 3 Haisma HJ. Et al., Cancer Gene Ther. 7, 901-904 (2000)
  • Non-patent document 4 Dmitriev I. et al., J. Viol. 74, 6875-6884 (2000)
  • Non-patent document 5 Wesseling JG. Et al., Gene Ther. 8, 969-976 (200 1)
  • Non-Patent Document 6 Nieklin SA. Et al., Circulation 102, 231-237 (2000)
  • Non-Patent Document 7 Nettelbeck DM. Et al., Mol. Ther. 3, 882—891 (2 001)
  • An object of the present invention is to provide a method for introducing a gene into a target cell using a vector into which the gene has been incorporated.
  • the method of the present invention comprises:
  • a method for introducing a gene into a target cell using a vector incorporating the gene is described below.
  • the present invention also provides a conjugate of a ligand for a cell surface receptor of a target cell with a vector surface protein, and the use of the conjugate in the above-described gene transfer method of the present invention.
  • VEGF vascular endothelial growth factor
  • FIG. 1 is a view showing the effect of mixing knobscFv-VEGF protein on gene transfer under low temperature.
  • FIG. 2 is a view showing FACS data.
  • the vertical axis indicates the number of cells, and the horizontal axis indicates GFP intensity.
  • NC Negative control (no infection);
  • C (l) (Yes infections, KnobscFv- mixing teeth of VEGF protein);
  • C (1) V ( 20) ( Yes infections, KnobscFv- incorporation of VEGF protein 20 / zeta 8 ⁇ 1).
  • N nega GFP +: indicates GFP positive.
  • a method for coupling and targeting a protein ligand to an antibody against a fiber knob of an adenovirus vector has already been reported for VEGF protein (Watkins SJ et al., Gene Therapy 4, 1004-1012 (1997 )).
  • the method of the present invention is an improvement of the method for the purpose of gene transfer under adverse conditions such as low temperatures.
  • the present invention makes it possible to use VEGF protein even under adverse conditions such as low temperature, and in particular, to enable gene transfer to the vascular endothelium of a transplanted organ.
  • the method of the present invention uses a vector into which a gene has been incorporated to transfer the gene to a target cell. How to introduce a child
  • the vector in the present invention is not particularly limited as long as it has a function of expressing a desired gene in a cell by a biological method and producing a desired protein.
  • the present invention utilizes a conjugate of a vector surface protein and a ligand for the cell surface receptor of the target cell. Therefore, vectors that can utilize surface proteins, for example, viral vectors, phage vectors, plasmids, ribosomes, and the like are applicable in the present invention.
  • the binding of the ligand to the cell surface receptor of the target cell to the vector surface protein is carried out by first, a substance that recognizes the surface protein of the vector, preferably an antibody, and the target cell
  • a conjugate of a ligand to the cell surface receptor of the present invention may be prepared, and such a conjugate may be mixed with a vector.
  • the ligand for the cell surface receptor binds to the surface protein of the vector via a substance that recognizes the surface protein of the vector.
  • the vector surface protein and a ligand for the cell surface receptor of the target cell may be expressed as a fusion protein on the particle surface of the vector without using a substance that recognizes the surface protein.
  • Such a fusion protein Vectors capable of expressing the same are also included in the scope of the present invention because they can be specifically targeted to cell surface receptors of target cells.
  • a fusion protein of a vector surface protein and a ligand for a cell surface receptor of a target cell is prepared, and the fusion protein is chemically covalently bound to the vector.
  • the vector of the present invention is preferably a paramicrovirus vector including an adenovirus vector, an adeno-associated virus (AAV) vector, a retrowinores vector, a henoreus innores vector, a Sendai winores vector.
  • AAV adeno-associated virus
  • Orthomyxovirus vectors containing influenza virus, and adenovirus vector Z adeno-associated virus hybrid vector are selected as well as virus vectors that can be selected as a group.
  • it is an adenovirus vector.
  • the method of the present invention can also be used with non-viral vectors such as ribosomes.
  • non-viral vectors such as ribosomes, phage vectors and plasmids can be used.
  • General methods for gene transfer and gene expression using ribosomes are described, for example, in the manual for ribosome experiments in life sciences, edited by Hiroshi Terada and Tetsuro Yoshimura, Springer-I 'Fairerak Tokyo (1992), and Miller AD, Methods Mol. Med References such as 90, 107-137, (2004), etc.
  • Phage vectors One example includes a lambda phage vector and an M13 vector.
  • the type of the gene incorporated into the vector and introduced into the target cell is not particularly limited, and any gene can be used. Genes involved directly or indirectly in disease prevention and Z or cure, tissue and organ maintenance and Z or repair, and the like. As the disease, clinical application is possible, for example, by introducing a gene into a new blood vessel of a cancer in addition to a transplanted organ, or introducing a gene into an ischemic cardiovascular disease such as myocardial infarction. Alternatively, genes encoding factors involved in immunosuppression can be used Noh. As used herein, “a gene involved in immunosuppression refers to a protein or peptide having an activity of weakening, circumventing, or positively inducing an immune response.
  • a specific cell for example, a cancer cell
  • genes encoding lysine, herpes virus thymidine kinase (HSV-tk), yeast cytidine deaminase, and the like can be used.
  • vascular endothelial growth factor VEGF
  • Tie-1 Tie-2
  • CD34 PECAM
  • E-selectin VE-cadherin
  • von Willebrand von Willebrand
  • CD146 CD36
  • thrombomodulin indegrin
  • V angiopoietin, keratinocyte growth factor (KGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF)
  • NCBI fibroblast growth factor
  • the gene incorporated into the vector may be a "marker gene".
  • the term “marker” refers to a gene encoding a protein suitable for immunohistological staining or direct or indirect immunofluorescent staining of a tissue or a cell. These marker genes are expressed in transformed cells and can be detected by a known detection method depending on the type of the marker gene. Therefore, the localization of the transformed cells in the tissue can be observed using a fluorescence microscope by direct or indirect immunofluorescence staining. It is also possible to detect and observe using known flow cytometry (FCM) and FACS (flororescenc activated cell sorter).
  • FCM flow cytometry
  • FACS fluorescenc activated cell sorter
  • the size (length) of a gene that can be incorporated into a vector is appropriately selected depending on the type of the vector.
  • a gene having a length of 6bp-5kbp can be inserted.
  • an adenovirus vector it is preferably 18 bp-2 kbp.
  • a gene with a length of 6 bp to 40 kbp can be inserted.
  • ribosomes it is possible to integrate a gene with a length of 6bp-20kbp.
  • the conjugate of the present invention includes a step of binding a ligand for a cell surface receptor of a target cell to a vector surface protein before or simultaneously with infection of the target cell with the vector.
  • the "surface protein of a vector” is present on the surface of a vector, and is preferably recognized by a substance that specifically recognizes the surface protein (for example, a specific antibody).
  • a possible protein Appropriate vector-surface proteins can be used as appropriate depending on the type of vector.
  • fiber proteins such as “knob”, hexon, and penton base can be used as surface proteins.
  • Knob proteins are fibrous proteins present on the surface of adenovirus and are known to initiate infection with adenovirus with high binding affinity for adenovirus receptors.
  • adeno-associated virus (AAV) vector is a forcepsid protein (VP1, VP2, VP3)
  • retrovirus vector is envelope protein (Env)
  • Virus vectors are gB and gC present in the envelope
  • Sendai virus vectors are fusion protein (F)
  • HN protein HN
  • adeno-associated virus hybrid vector is adenovirus “knob”. Hexon, penton base, etc. are available.
  • a ribosome surface protein for example, HVJ-ribosome constructed by utilizing the membrane fusion ability of Sendai virus, in the case of Sendai virus fusion protein (F) and HN protein (HN ) Is available.
  • the "ligand for the cell surface receptor of the target cell” can be appropriately selected depending on the type of the target cell into which the gene is to be introduced. For example, it is known that receptors for vascular endothelial growth factor (VEGF) are highly expressed in the vascular system. Therefore, VEGF can be used in the present invention to target a vector containing the gene to cells of the vascular system. Tie-1, Tie-2, CD34 (PECAM), E-selectin, VE-cadherin, von Willebrand factor, CD146, CD36, thrombomodulin, indegulin (V (3 , Angiopoietin, epidermal growth factor (EGF) and fibroblast growth factor (FGF) also target vascular cells. Keratinocyte growth factor (KGF) targets the epithelium, especially the lung airways.
  • VEGF vascular endothelial growth factor
  • the binding of the ligand to the cell surface receptor of the target cell to the surface protein of the vector is performed by, first, a substance that recognizes the surface protein of the vector, preferably an antibody, and the target cell
  • a conjugate of a ligand to a cell surface receptor of the present invention may be prepared, and such a conjugate may be mixed with a vector.
  • the ligand for the cell surface receptor binds to the vector surface protein via a substance that recognizes the vector surface protein.
  • the method of the present invention comprises, in one aspect thereof,
  • the substance that recognizes the surface protein of the vector is not particularly limited as long as it can specifically recognize the surface protein of the vector. It includes the extracellular domain of the receptor on the cell side recognized by the antibody and the vector. Preferably, it is an antibody.
  • the "antibody” is preferably a monoclonal antibody that can recognize the "surface protein of the vector".
  • Antibodies specific for the vector surface protein can be generated using known methods. For example, it can be obtained by preparing a phage display library from the spleen of an immunized animal (for example, mouse) immunized with the vector surface protein and screening for an antibody specific to the antigen.
  • Antibody refers to an intact antibody, including: polyclonal antibodies (see, eg, Ant ibodies: A Laboratory Manual, Harlow and Lane (eds.), Old spring Harbor Laboratory Press (1988)), and Monoclonal antibodies (see Monoclonal al Antibodies: A New Dimension in Biological Analysis, Plenum Press, Kennet, McKearn and Bechtol (ed.) (1980)). [0030] “Antibody” refers to an antibody fragment produced by recombinant DNA methods or enzymatic or chemical cleavage of an intact antibody, such as F (ab), F (ab,), F (ab,), Fv, Fc , And single-chain anti-
  • antibody also refers to a bispecific or bifunctional antibody that is an artificial hybrid antibody having two different heavy Z light chain pairs and two different binding sites.
  • Bispecific antibodies can be prepared by a variety of methods, including hybridoma fusion or Fab 'fragment conjugation (Songsivilai et al., 1990, Clin. Exp. Immunol., 79: 315-321; Kostelny et al.). , 1992, J. Immunol., 148: 1547-1553;).
  • Antibody also refers to a chimeric antibody, ie, an antibody in which a human antibody immunoglobulin constant domain is bound to one or more non-human antibody immunoglobulin variable domains, or a fragment thereof.
  • Antibodies include "humanized antibodies”, “minibodies”, and transgenic animals capable of producing human antibodies, including transgenic animals that contain a certain percentage of human antibody-producing genes but do not produce endogenous antibodies. Includes antibodies produced by
  • variable regions of the heavy and light chains of an antibody contain an antigen-binding site, and the DNAs of both regions are linked by a linker, and expressed in a host cell to form a single-chain having an antigen-binding ability.
  • FV protein FV protein
  • a gene encoding both the heavy chain and light chain variable regions of an antibody is expressed in a host cell such as Escherichia coli, whereby an antibody protein capable of binding to a cell surface protein of a vector is obtained. Can be obtained in large quantities. This is cheaper than maintaining monoclonal antibodies obtained by culturing in a medium requiring serum, and application to enzyme immunoassay can be expected.
  • the antibody is preferably a single-chain Fv protein (sFv).
  • the conjugate of the substance that recognizes the surface protein of the vector and the ligand for the cell surface receptor of the target cell can be prepared using a known method.
  • the substance is a protein (preferably an antibody)
  • the protein of the present invention is fused by expressing the gene encoding the substance and the gene encoding the ligand in the same reading frame (in flame). It may be expressed as a protein.
  • the fusion protein can be prepared by any genetic engineering method, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Brother Edition 3, Cold Spring Harbor Laboratory, New York It can be carried out in accordance with the protein expression method described in Ichido 'Spring', Ichibar (2001).
  • the gene encoding an antibody against the surface protein of the vector can be obtained, for example, from an antibody-producing hybridoma based on the amino acid sequence of the antibody protein.
  • mRNA is prepared from these hybridomas by a known method, and based on the mRNA, a single-stranded cDNA is synthesized using reverse transcriptase. Based on the amino acid sequence or base sequence of the antibody, PCR, hybridization, and the like are performed.
  • the gene of the present invention can be selectively obtained. Such a method is well known, and those skilled in the art can easily isolate the gene of the present invention based on the disclosure in the present specification.
  • a cDNA library of cells producing the desired antibody is constructed, and cDNAs encoding the highly conserved immunoglobulin heavy and light chain constant regions are used as probes to prepare the cDNA library.
  • the rally may be screened to isolate the light and heavy chain cDNAs of the desired antibody.
  • genes encoding the variable regions of both the heavy and light chains of the antibody may be used to express the sFv antibody.
  • a gene database for example, NCBI. Therefore, those skilled in the art can use the obtained genetic information to integrate the gene into an expression vector or the like.
  • the VEGF gene has been registered with NCBI as AB021221, AF486837.
  • a substance that recognizes a surface protein of a vector and a ligand protein for the cell surface receptor of the target cell may be bound by a linker or the like.
  • the linkers include, for example, dimethylsuccinate imidate dihydrochloride (DMS), suberic acid di-N-hydroxysuccinimide ester (DSS), tartaric acid N-hydroxydisuccinimide ester (DST), and p-phenyl-bismaleimide (pPDM) , Methyl-4-mercaptobutyrimidate hydrochloride (MBI), methyl-4 azidobenzimidate hydrochloride (ABI) and the like.
  • DMS dimethylsuccinate imidate dihydrochloride
  • DSS suberic acid di-N-hydroxysuccinimide ester
  • DST tartaric acid N-hydroxydisuccinimide ester
  • pPDM p-phenyl-bismaleimide
  • MBI Methyl-4-mercapto
  • the binding of a substance (preferably a protein) to the surface protein of the vector using the linker and the ligand protein to the cell surface receptor of the target cell can be performed, for example, by Seismic Chemistry Experiment Course 2 Chemistry of Proteins It can be carried out according to the method described in p.604-618 (1987).
  • the mixing ratio of the vector with the conjugate is, for example, 1 x 10 8 pfuZml of the vector, the conjugate is preferably 2.5 g to 20 gZml, more preferably 10 g to 20 gZml. is there.
  • the present invention is characterized by specifically promoting the infection of a vector with a target cell by utilizing a surface protein on the vector and a ligand bound to the cell surface receptor of the target cell. Things. Therefore, the vector surface protein and the ligand for the cell surface receptor of the target cell may be expressed as a fusion protein on the particle surface of the vector by a genetic engineering technique without using a substance that recognizes the surface protein. Specifically, the protein of the present invention is expressed as a fusion protein by expressing the gene encoding the vector surface protein and the ligand gene for the cell surface receptor of the target cell in the same reading frame (in flame). It is possible to do so.
  • the fusion protein can be prepared by any genetic engineering techniques, for example, as described in Sambrook et al., Molecular Science: A Laboratory Manual, Brother Edition 3, Cold spring Harb or Laboratory, Cold 'Spring' Nover, NY (2001). It can be carried out according to the protein expression method.
  • the gene encoding the fusion protein may be integrated into the viral genome using a known technique.
  • the fusion protein can be expressed on the surface of the ribosome vector using an appropriate expression vector, for example, a plasmid.
  • a conjugate of the vector surface protein and the ligand for the cell surface receptor of the target cell may be separately prepared, and the conjugate may be chemically covalently bonded to the vector surface.
  • Conjugates of the vector surface protein and the ligand for the cell surface receptor of the target cell are preferably prepared as a fusion protein.
  • the conjugate of the substance that recognizes the surface protein of the vector and the ligand protein for the cell surface receptor of the target cell may form the vector surface protein and the ligand for the cell surface receptor of the target cell. You may couple
  • a conjugate preferably a fusion protein
  • An embodiment in which a conjugate is separately prepared is useful, for example, when a plasmid vector is applied as the vector of the present invention.
  • the present invention includes a step 1) of binding a ligand for a cell surface receptor of a target cell to a vector surface protein before or simultaneously with the infection of the vector with a target cell.
  • the surface protein on the vector binds to the ligand for the cell surface receptor, while the ligand for the cell surface receptor of the target cell binds to the cell surface receptor, thereby specifically promoting the infection of the vector to the target cell. Is performed.
  • knobFv-VEGF protein was mixed with 1 ⁇ 10 8 pfuZml of adenovirus, and as the amount of knobFv-VEGF protein increased, In addition, the percentage of gene-expressing cells and MCS were also high ( Figure 1).
  • Gene transfer by a biological method is generally carried out by bringing cells into contact with a gene at room temperature under oxygen for a relatively long time in order to achieve efficient gene transfer.
  • clinical practice requires gene transfer under special adverse conditions of low temperature, low oxygen, and short contact time. Nevertheless, a method for efficiently performing gene transfer under such so-called adverse conditions has not been provided despite the necessity.
  • the gene transfer method of the present invention includes, in order to solve the above problem, infecting the cell with the vector under at least one condition of low temperature, low oxygen and short time in step 2). .
  • step 1) infection of the vector with the target cell is specifically promoted by binding a ligand for the cell surface receptor of the target cell to the surface protein of the vector.
  • a ligand for the cell surface receptor of the target cell to the surface protein of the vector.
  • the term "low temperature” refers to a temperature lower than normal temperature (less than normal temperature), preferably 10 ° C or lower, more preferably 7 ° C or lower, and most preferably 4 ° C or lower.
  • the lower limit temperature is at least o ° c or more in consideration of the state of the target cell, the fibrous tissue and the like. Cold conditions can be achieved, for example, by performing the infection in an ice slush tray or in an ice nos (ice bath).
  • under hypoxia means a condition in which blood is blocked and oxygen is not substantially delivered to tissues.
  • hypoxic conditions after 15 minutes or more after blood cutoff more preferably hypoxic conditions after 1 hour or more, 3 hours or more, or 24 hours or more after blood cutoff It is. In the harshest conditions, it is desirable that gene transfer by vector infection under hypoxic conditions 72 hours or more after blood blockage is possible.
  • the term "short time” generally means a time shorter than a time for infecting a target cell with a vector in a gene transfer method using a vector.
  • the vector in the case of a viral vector such as Adenovirus vector, the vector is generally infected for 1 hour to 24 hours.
  • the infection time is about 1 to 24 hours.
  • the infection time of the vector to the target cell is preferably 1 hour or less, more preferably 30 minutes or less, and most preferably 15 minutes or less.
  • a desired gene can be introduced into a target cell with high efficiency.
  • the target cell is not particularly limited as long as it can be transformed by a biological method using the vector. It may be a cultured cell in vitro, or a cell in an in vivo or in vivo tissue for transplantation or in a living tissue! ⁇ .
  • the type of cells those which present a cell surface receptor which can be used particularly on the cell surface, for example, vascular endothelial cells, epidermal cells, dermal cells, epithelial cells, keratinocytes and the like are preferable.
  • the method of the present invention can also be clinically applied, for example, to gene transfer to transplanted organs and other neovascular vessels of cancer and gene transfer to ischemic cardiovascular diseases such as myocardial infarction.
  • VEGF gene (NCBI databank, AB021221, AF486837) (SEQ ID NO: 1) the pcDNA3 1 (Invitrogen, Carlsbad, CA ) Sabukuro the EcoRI site of -.
  • the ring with plasmid (P cDNA3 1ZVEGF.) was prepared.
  • Primer 1 (5′—gcggccg cttccatgaactt—3 ′) (Tori selfie 2)
  • Primer 2 (5, —gcacactcgaggctgatcag—3) designed to add the NotlZXhoI restriction enzyme site to the type I plasmid ') (SEQ ID NO: 3) was used for PCR.
  • a VEGF gene (NotlZXhoI) fragment was prepared.
  • knob scFv-EGF gene (Watkins SJ et al., Gene Therapy 4, 1004-1012 (1997)) provided by the University of Bristol (Hawkins RE) was cut out with Ncol ZEcoRI. This fragment was inserted into the EcoRl restriction enzyme site of pcDNA3.1 ZHis A (Invitrogen) by blunt-end ligation to construct pcDNA3.1 / HisA / knobs cFv-EGF. This pcDNA3.1 / HisA / knobscFv—EGF was cut with NotlZX hoi to cut out the EGF gene (NotlZXhoI fragment). Instead, the VEGF gene (NotlZXhoI) fragment prepared above was inserted by ligation to prepare pcDNA3.1 / His AZknobscFv-VEGF.
  • a gene was introduced into COS7 by the lipofectamine method (Invitrogen). (0418 sulfate: 018-0—: 61 ⁇ Rockville, MD). After lysing the selected cells, knobscFv-VEGF protein was purified using a purification system of Ni-NTA Purification system with anti-Xpress TM antibody (Invitrogen) according to the attached protocol. Finally, the cells were treated with enterokinase to cleave the His and X-press tags.
  • the knobscFv-VEGF protein prepared in Example 1 was mixed with an adenovirus vector incorporating the GFP gene (adexGFP: RIKEN BioResource Center (RDB No 1727)). It was prepared by summing. Specifically, adexGFP of lxl0 8 pfuZml, mixed at various concentrations KnobFv- VEGF protein (0- 20 g / ml), and incubated Chillon in 1 hour incubator until use in subsequent experiments (until the next day) in a refrigerator saved.
  • adexGFP RIKEN BioResource Center
  • porcine vascular endothelial cells were prepared as follows. Porcine aortic force The vascular endothelium was mechanically removed, and after 5 passages, it was confirmed that it was a vascular endothelial cell by the incorporation of Dil acetylated LDL (Di-Ac-LDL: Biogenesis L TD). .
  • the obtained vascular endothelial cells were confluent in a 6-well plate and infected with MOI 10. Specifically, in the case of low-temperature infection, a 6-well plate was placed in an ice slush tray and infected for 1 hour. Then, the medium was changed to a D-MEM medium containing 10% FCS, and cultured in an incubator (37 ° C) for 24 hours. In the case of room temperature infection, the cells were infected in an incubator (37 ° C) for 1 hour, and then the medium was changed to D-MEM containing 10% FCS, and cultured in an incubator ( 37 ° C) for 24 hours.
  • FIG. 1 shows the results.
  • FIG. 1 it was determined that the expression of the GFP gene was increased by mixing knobFv-VEGF protein with respect to the extremely low expression efficiency (C (l)) at low temperature. MCS values are expressed as relative values.
  • C (l) extremely low expression efficiency
  • MCS values are expressed as relative values.
  • the GFP gene expression was increased in a dose-dependent manner.
  • the presence of knobscFv-V EGF protein bound to adexGFP proves that gene transfer via the VEGF receptor functions effectively at low temperatures and under special conditions, and improves both gene expression efficiency and expression level. It was done.
  • FIG. 2 shows FACS data.
  • the use of the method of the present invention makes it possible for the first time to perform gene transfer with high efficiency even under adverse conditions such as low temperature, low oxygen, and short time.
  • infection was performed at a low temperature of 0 ° C. for 1 hour.
  • 0-20 ⁇ gZml of knobFv-VEGF protein was mixed with lxl0 8 pfuZml of adenovirus, the higher the amount of knobFv-VEGF protein, the higher the percentage of gene-expressing cells and MCS (Fig. 1). ).
  • knobFv-VEGF protein at 10 / z gZml showed approximately the same ratio of gene-expressing cells and MCS as in the case of infection at room temperature for 1 hour.
  • the transfection efficiency was increased by about 20% (about 68% and also about 87%) and the MCS was increased by about 4.7 times as compared to the case of infection at room temperature for 1 hour (10. 1 to 47.8).
  • the gene transfer efficiency is about 2.7 times (about 32% to about 87%) and the MSC is about 22 times (2%) compared to the case without knobFv-VEGF protein. . 2 power also increased by 47. 8).
  • the method of the present invention preferably achieves the same gene transfer efficiency as that in the case where the conjugate is not mixed without specific adverse conditions by mixing the conjugate even under specific adverse conditions. Things.
  • the present invention also relates to a conjugate of a ligand for a cell surface receptor of a target cell and a vector surface protein, and the use of the conjugate in the above-described gene transfer method of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il est fourni un procédé caractérisé en ce qu'il comprend les étapes consistant à : (1) lier un ligand devant être reçu par un récepteur de surface de cellule de la cellule cible à une protéine de surface d'un vecteur ; et (2) infecter la cellule avec le vecteur résultant dans au moins une des conditions choisie entre une basse température, une faible teneur en oxygène et une courte durée.
PCT/JP2005/006182 2004-03-31 2005-03-30 Procédé d'introduction d'un gène dans une cellule cible WO2005095623A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004107623A JP2007228802A (ja) 2004-03-31 2004-03-31 標的細胞への遺伝子の導入方法
JP2004-107623 2004-03-31

Publications (1)

Publication Number Publication Date
WO2005095623A1 true WO2005095623A1 (fr) 2005-10-13

Family

ID=35063794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006182 WO2005095623A1 (fr) 2004-03-31 2005-03-30 Procédé d'introduction d'un gène dans une cellule cible

Country Status (2)

Country Link
JP (1) JP2007228802A (fr)
WO (1) WO2005095623A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501219A (ja) * 1995-11-28 1999-02-02 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
WO2002096939A2 (fr) * 2001-05-30 2002-12-05 Transgene S.A. Proteine d'adenovirus ix, ses domaines participant a l'ensemble de capside, activite transcriptionnelle et reorganisation nucleaire
WO2003004661A2 (fr) * 2001-07-06 2003-01-16 Crucell Holland B.V. Vecteurs d'apport de genes a specificite de type cellulaire pour les cellules souches mesenchymateuses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501219A (ja) * 1995-11-28 1999-02-02 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
WO2002096939A2 (fr) * 2001-05-30 2002-12-05 Transgene S.A. Proteine d'adenovirus ix, ses domaines participant a l'ensemble de capside, activite transcriptionnelle et reorganisation nucleaire
WO2003004661A2 (fr) * 2001-07-06 2003-01-16 Crucell Holland B.V. Vecteurs d'apport de genes a specificite de type cellulaire pour les cellules souches mesenchymateuses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHURANA V.G. ET AL: "A direct mechanical method for accurate and efficient adenoviral vector delivery to tissues", GENE THERAPY, vol. 10, 2003, pages 443 - 452, XP002990104 *
OMORI N. ET AL: "Modification of a fiber protein in an adenovirus vector improves in vitro gene transfer efficiency to the mouse microglial cell line", NEUROSCIENCE LETTERS, vol. 324, 2002, pages 145 - 148, XP002990103 *
SHAKED A. ET AL: "Adenovirus-mediated gene transfer in the transplant setting", TRANSPLANTATION, vol. 57, no. 10, 1994, pages 1508 - 1511, XP002990105 *

Also Published As

Publication number Publication date
JP2007228802A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
EP2508603B1 (fr) Système pour accroître l'expression génétique, et vecteur de support pour un tel système
KR101614369B1 (ko) 유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용
CN109576292B (zh) 一种抗体文库的构建方法及其应用
CN107043774B (zh) 一种嵌合强启动子及其用途
WO2008015675A2 (fr) Polypeptides et polynucléotides les codant et leur utilisation dans le traitement d'affections médicales associées à l'ischémie
KR20200090927A (ko) 내이에 대한 치료적 항체의 aav-매개 전달
JP2022105139A (ja) キメラｎｏｔｃｈ受容体の免疫原性を低下させる方法及び組成物
JP6162224B2 (ja) 血管組織の形質導入のためのアデノウイルスベクター
TWI293307B (en) A liver-specific chimeric regulatory sequence and use thereof
US9029133B2 (en) Recombinant virus comprising an intact tumor-therapeutic antibody with human constant regions and the use thereof
WO2000024912A1 (fr) Utilisation d'un motif d'arn auto-clivant
WO2005095623A1 (fr) Procédé d'introduction d'un gène dans une cellule cible
WO2022116528A1 (fr) Arn circulaire, vaccin contenant un arn circulaire et kit de détection d'un nouvel anticorps neutralisant le coronavirus
CN104558181A (zh) 靶向b淋巴瘤细胞的人源单链抗体
CN105026573A (zh) 用于单引物扩增的基因特异模板的制备
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
Lee et al. Multicistronic IVT mRNA for simultaneous expression of multiple fluorescent proteins
EA023016B1 (ru) Составной белок
WO2007061141A1 (fr) Paramyxovirus mutant et procede pour la production de celui-ci
CA3070936A1 (fr) Proteine de fusion
CN117836420A (zh) 重组tert编码病毒基因组和运载体
Mazur et al. Biopanning of single-chain antibodies expressing phages reveals distinct expression patterns of angiogenic and arteriogenic vessels
WO2018169094A1 (fr) Procédé de création de cellules endothéliales vasculaires tumorales immortalisées d'origine humaine et cellules endothéliales vasculaires tumorales immortalisées d'origine humaine
García Gallardo Developing cardiomyocyte specific vectors
CA3215812A1 (fr) Compositions et methodes pour le traitement d'une maladie oculaire associee a l'angiogenese

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP